Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 14/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 7/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 5/20 | 0.47 |
| ▸ | PLA2G2E | Q9NZK7 | 5/20 | 0.47 |
| ▸ | PLA2G5 | P39877 | 4/20 | 0.47 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.46 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.46 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.46 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.46 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.46 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862383 | 1.00 | PTPN1 (0.48) | PTPN1PTPN2PTPN6PLA2G2APLA2G1B | |
| SCHEMBL7955041 | 0.92 | PLA2G2A (0.49) | PTPN1PTPN2PTPN6PLA2G2APLA2G1B | |
| SCHEMBL7966203 | 0.91 | PLA2G2A (0.46) | PTPN1PTPN6PLA2G2APLA2G1BPLA2G10 | |
| SCHEMBL29862573 | 0.91 | PLA2G2A (0.54) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL818840 | 0.91 | PLA2G2A (0.54) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL818733 | 0.89 | PLA2G2A (0.50) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL29862408 | 0.89 | PLA2G2A (0.50) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL8067153 | 0.89 | PLA2G2A (0.48) | PTPN1PTPN2PTPN6PLA2G2APLA2G1B | |
| SCHEMBL7631728 | 0.89 | PLA2G2A (0.48) | PTPN1PTPN2PTPN6PLA2G2APLA2G1B | |
| SCHEMBL6695557 | 0.88 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043991-A4 | TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| JP-2004503586-A | — | — | 2004-02-05 | — | — | JP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | claimed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | claimed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| JP-2001522884-A | — | — | 2001-11-20 | — | — | JP | claimed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | claimed |
| EP-1043991-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-18 | — | — | EP | claimed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | PTPN1 2205/4885PTPN2 1367/4885PTPN6 2135/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | PTPN1 2224/4885PTPN2 2272/4885PTPN6 2559/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PTPN1 3005/4885PTPN2 2035/4885PTPN6 3108/4885 |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, SPINT2 | PTPN1 2375/4885PTPN2 1219/4885PTPN6 2472/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | PTPN1 816/4885PTPN2 532/4885PTPN6 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.